Vaccine Trial Volunteer Tests Positive for Covid-19 in Indonesia’s West Java

When the results of the swab test came out, the volunteer was confirmed positive for the Covid-19.

“The results of the swab test was not from the research team, but from the nasopharyngeal swab testing program by the government,” he said.

Also read: Indonesia’s Bio Farma to Get 50M Doses of Covid-19 Bulk Vaccine Starting November

Kusnandi urged the volunteers to follow the Covid-19 health protocols. He said that in the clinical trials not all volunteers were injected with the candidate vaccine but some were with placebo.

The clinical trial volunteers will still have their health monitored for six months after receiving the last vaccine injection, he added.

Kompas.com reported that nearly 2,200 Indonesians have volunteered for the Covid-19 vaccine trials, exceeding the initial target of 1,620 as previously announced.

Also read: Nearly 2,200 Volunteers Sign Up for Covid-19 Vaccine Trials in Indonesia

Not all the volunteers, however, meet the clinical trial requirements. About 10 percent of people failed the screening due to hypertension.

During the first batch of the injection on August 11-15, 110 volunteers received the shots from the vaccine's clinical trial team in Bandung, West Java. It is estimated that the vaccines will be tested on 540 volunteers by November and around 1,620 people by January.

The program was part of Phase 3 clinical trials jointly conducted by Indonesian vaccine manufacturer PT Bio Farma and biopharmaceutical company Sinovac Biotech Ltd of China.
PT Bio Farma planned to produce up to 250 million doses of the Covid-19 vaccine early next year after receiving 2,400 candidate vaccines from Sinovac.

(Writer: Reni Susanti | Editor : Farid Assifa, Setyo Puji)

Source: https://regional.kompas.com/read/2020/09/11/05400021/bepergian-ke-luar-kota-relawan-uji-vaksin-buatan-china-terpapar-covid-19-ini?page=2.

https://regional.kompas.com/read/2020/09/10/19594611/relawan-yang-disuntik-vaksin-buatan-china-terpapar-covid-19.